文献速递冠心病

JCAD蛋白预测高残余风险急性冠脉综合征患者的不良心血管事件

The junctional protein associated with coronary artery disease predicts adverse cardiovascular events in patients with acute coronary syndromes at high residual risk.
PubMed 文献 · Eur Heart J · 2026-01-01

本研究在SPUM-ACS队列(n=4787)中分析残余脂质风险、残余炎症风险或两者兼有的ACS患者,发现这些患者1年MACE风险高于倾向评分匹配的对照。JCAD与MACE风险独立相关,并在RISK-PPCI队列(n=496)中外部验证,JCAD水平与内源性纤溶受损正相关。

要点

  • 残余脂质风险、残余炎症风险或两者兼有的ACS患者1年MACE风险显著升高。
  • JCAD与MACE风险独立相关,且在残余炎症风险患者中关联更强。
  • JCAD水平与内源性纤溶受损正相关,可能通过凝血和纤溶途径介导残余风险。

核心结论

  • ACS患者伴残余脂质风险、残余炎症风险或两者兼有时缺血风险高。
  • JCAD通过调节凝血和内源性纤溶,是解决指南推荐治疗后残余风险的有前景的候选靶点。

研究设计与样本

  • 发现队列SPUM-ACS(n=4787)中识别残余脂质风险、残余炎症风险或两者兼有的ACS患者,并与倾向评分匹配的对照比较。
  • 独立队列RISK-PPCI(n=496)评估JCAD对内源性凝血和纤溶的影响,并外部验证JCAD-MACE关联。

主要发现

  • 1年时,残余脂质风险、残余炎症风险或两者兼有患者较对照的MACE风险分别HR 1.55(95%CI 1.08-2.23)、HR 1.80(95%CI 1.24-2.61)、HR 1.75(95%CI 1.12-2.75)。
  • 残余脂质风险患者中,MACE风险随hs-CRP和JCAD升高,单变量HR每log2增加分别为1.17(95%CI 1.06-1.30)和1.29(95%CI 1.03-1.62),多变量aHR分别为1.16(95%CI 1.03-1.30)和1.27(95%CI 1.01-1.60)。
  • 残余炎症风险患者中,JCAD每log2增加MACE风险HR 1.28(95%CI 1.03-1.59),多变量aHR 1.31(95%CI 1.04-1.65)。
  • 残余脂质和炎症风险患者中,JCAD每log2增加MACE风险HR 1.45(95%CI 1.09-1.92),多变量aHR 1.47(95%CI 1.11-1.97)。
  • 血浆JCAD水平与内源性纤溶受损指标正相关,JCAD-MACE关联在外部验证队列中同样观察。

关键数值与推荐

  • 残余脂质风险定义为他汀治疗下LDL-c ≥70 mg/dL(≥1.8 mmol/L)。
  • 残余炎症风险定义为他汀治疗下hs-CRP ≥2.0 mg/L。
  • 残余脂质和炎症风险定义为他汀治疗下LDL-c ≥70 mg/dL且hs-CRP ≥2.0 mg/L。

临床怎么用

  • 对于接受指南推荐治疗的ACS患者,可评估残余脂质和炎症风险以识别高危人群。
  • JCAD可能作为新型标志物或治疗靶点,用于管理ACS患者的残余风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with acute coronary syndromes (ACS) are at high ischaemic risk to which cholesterol, inflammation, and yet-to-be-identified pathways jointly contribute. The junctional protein associated with coronary artery disease (JCAD) drives incident cardiovascular events by acting on coagulation and fibrinolysis. This study aimed to assess whether JCAD serves as a novel marker of or target to address residual risk. METHODS: In the discovery cohort (SPUM-ACS; n = 4787), ACS patients at residual lipid risk [RLR; on-statin LDL cholesterol (LDL-c) ≥70 mg/dL or ≥1.8 mmol/L], residual inflammatory risk [RIR; on-statin high-sensitivity C-reactive protein (hs-CRP) ≥2.0 mg/L], or both (RILR; on-statin LDL-c ≥70 mg/dL and hs-CRP ≥2.0 mg/L) were identified and compared with propensity-score matched controls. Contributions of hs-CRP, LDL-c and JCAD to recurrent major adverse cardiovascular events (MACE) were analysed. In an independent cohort (RISK-PPCI study; n = 496), effects of JCAD on endogenous coagulation and fibrinolysis were gauged, and JCAD-MACE associations were externally validated. RESULTS: At 1 year, patients at RLR, RIR, or RILR were at higher MACE risk as compared to controls [hazard ratio (HR), 1.55, 95% confidence interval (CI) 1.08-2.23; HR 1.80, 95% CI 1.24-2.61; and HR 1.75, 95% CI 1.12-2.75, respectively]. In those at RLR, MACE risk rose with increasing hs-CRP and JCAD, respectively, in uni- (HR per log2 increase, 1.17, 95% CI 1.06-1.30; HR 1.29, 95% CI 1.03-1.62) and multivariable-adjusted models [adjusted (a)HR 1.16, 95% CI 1.03-1.30; aHR 1.27, 95% CI 1.01-1.60]. In those at RIR, MACE risk increased 1.28-fold per log2 increase in JCAD (HR 1.28, 95% CI 1.03-1.59), which prevailed in multivariable-adjusted models (aHR 1.31, 95% CI 1.04-1.65). Similarly, in patients at RILR, MACE risk increased almost linearly with increasing JCAD (HR 1.45, 95% CI 1.09-1.92), independently of potential confounders (aHR 1.47, 95% CI 1.11-1.97). Plasma levels of JCAD correlated positively with proxies of impaired endogenous fibrinolysis, with the JCAD-MACE association being similarly observed in the external validation cohort. CONCLUSIONS: Acute coronary syndrome patients at RLR, RIR, or both are at high ischaemic risk. By modulating coagulation and endogenous fibrinolysis, JCAD represents a promising candidate to address the high residual risk that persists in ACS patients receiving guideline-recommended care. CLINICALTRIALS.GOV IDENTIFIERS: NCT01000701, NCT02562690.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Kraler, Liberale, Tirandi, et al. The junctional protein associated with coronary artery disease predicts adverse cardiovascular events in patients with acute coronary syndromes at high residual risk. Eur Heart J. 2026. PMID: 41430589. doi:10.1093/eurheartj/ehaf979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。